DILAPAN-S gains attention at BMFMS 2024: Two posters showcasing real-world data
Share:
DILAPAN-S, the non-pharmacological solution for cervical ripening, is gaining momentum within the medical community. At the British Maternal & Fetal Medicine Society (BMFMS) conference, held in Liverpool, UK, on April 25-26, 2024, valuable real-world data from UK hospitals were showcased in two informative posters.
For more details on the presented research, please refer to the provided link.
Research highlights:
- Real-World Efficacy and Safety: The first poster, “Multicentre National Retrospective Review of Outcomes Following Use of DILAPAN-S for Cervical Priming,” demonstrated that DILAPAN-S ensures efficacy and safety in real-world settings, including among high-risk patients. The findings confirm the absence of side effects and the versatility of DILAPAN-S for labour induction.
- Reduced Analgesic Needs: The second poster, “Analgesia Requirements During Induction of Labour with Synthetic Osmotic Dilator: Multicentre National Retrospective Review of Outcomes Following Use of DILAPAN-S for Cervical Priming,” revealed that the use of DILAPAN-S is associated with significantly low analgesic requirements. This reduction translates into a more comfortable experience for mothers.
These findings reinforce the potential of DILAPAN-S as a first-line induction agent, incl. an out-patient regimen. The product offers a cost-effective solution with a high safety profile and success rate for both mothers and healthcare providers.
Other recommended News
Other news
Upcoming events
- 27. 9.
- LIVE WEBINAR
- 8. 5.
